From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated ...

Truvada, which is also marketed by Gilead (GILD), is approved for use as both a PrEP therapy and treatment for HIV infection ...

To end the Latino HIV crisis, health programs must be developed, tailored and evolve to meet the health needs and preferences of our diverse Latino communities.

The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.

A new study from Tulane University finds that historical race-based lending practices are still impacting health today, ...

What caused some of the STD trends to improve? Several experts say one contributor is the growing use of an antibiotic as a ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment ...

Another factor may have been an increase in the number of health workers testing people for infections, doing contact tracing ...

Although sexually transmitted infections are still at an epidemic level in the US, scientists at the US Centers for Disease ...

The National HIV and AIDS Control Programme of the Ghana Health Service has reported over 34,000 new HIV infections detected ...

But Dr. Joseph McGowan, HIV services medical director at Northwell Health, said he hadn’t seen a noticeable decline in STI ...